|
WO2016187028A1
|
|
Heteroaryl compounds, synthesis thereof, and intermediates thereto
|
|
WO2016100452A2
|
|
Heteroaryl compounds and uses thereof
|
|
US2016159774A1
|
|
Heteroaryl compounds and uses thereof
|
|
WO2016025648A1
|
|
Combinations of an erk inhibitor and a raf inhibitor and related methods
|
|
TW201618785A
|
|
Methods of treatment using an ERK inhibitor
|
|
WO2016025639A1
|
|
Combinations of an erk inhibitor and a chemotherapeutic agent and related methods
|
|
WO2016025640A1
|
|
Heteroaryl compounds and uses thereof
|
|
WO2016025567A1
|
|
Oral formulations and uses thereof
|
|
WO2016025650A1
|
|
Combinations of an erk inhibitor and a cdk4/6 inhibitor and related methods
|
|
WO2016025649A1
|
|
Combinations of an erk inhibitor and a dot1l inhibitor and related methods
|
|
WO2016025652A1
|
|
Combinations of an erk inhibitor and a bcl-2 pathway modulator and related methods
|
|
WO2016025651A1
|
|
Combinations of an erk inhibitor and a tor inhibitor and related methods
|
|
WO2016025656A1
|
|
Combinations of an erk inhibitor and a pi3k inhibitor or dual pi3k/tor inhibitor and related methods
|
|
WO2016025641A1
|
|
Combinations of an erk inhibitor and an egfr inhibitor and related methods
|
|
US2017173011A1
|
|
Methods of treating a bruton's tyrosine kinase disease or disorder
|
|
US2014296233A1
|
|
Heteroaryl compounds and uses thereof
|
|
MX2015011514A
|
|
Heteroaryl compounds and uses thereof.
|
|
KR20150119012A
|
|
Erk inhibitors and uses thereof
|
|
CA2908098A1
|
|
Mk2 inhibitors and uses thereof
|
|
WO2014100748A1
|
|
Heteroaryl compounds and uses thereof
|
